Heparin-induced thrombocytopenia: A renal perspective

Nature Reviews Nephrology

Volumn 5, Issue 9, 2009, Pages 501-511

  Syed, Samaha ^a   Reilly, Robert F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN;

BOLUS INJECTION; CLINICAL FEATURE; DRUG MECHANISM; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTIBODIES; ANTICOAGULANTS; EDUCATION, MEDICAL, CONTINUING; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; THROMBOCYTOPENIA;

EID: 70349335697     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.125     Document Type: Review

References (85)

1. Ahmed, I., Majeed, A. & Powell, R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad. Med. J. 83, 575-582 (2007).
2. Weismann, R. E. & Tobin, R. W. Arterial embolism occurring during systemic heparin therapy. AMA Arch. Surgery 76, 219-225 (1958).
3. Rhodes, G. R., Dixon, R. H. & silver, D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol. Obstet. 136, 409-416 (1973).
4. Amiral, J. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 68, 95-96 (1992).
5. Reilly, R. F. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin. Dial. 16, 54-60 (2003).
6. Chuang, P., Parikh, C. & reilly, R. F. A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia. Am. J. Nephrol. 21, 226-231 (2001).
7. Chang, J. J. & Parikh, C. R. when heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin. Dial. 19, 297-304 (2006).
8. Warkentin, T. E., Chong, B. H. & Greinacher, A. Heparin-induced thrombocytopenia: toward consensus. Thromb. Haemost. 79, 1-7 (1998).
9. Kelton, J. G. & warkentin, T. E. Heparin-induced thrombocytopenia: a historical perspective. Blood 112, 2607-2615 (2008).
10. Warkentin, T. E. & Kelton, J. G. Delayed onset heparin-induced thrombocytopenia and thrombosis. Ann. Intern. Med. 135, 502-506 (2001).
11. Kelton, J. G., Hursting, M. J., Heddle, N. & Lewis, B. E. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul. Fibrinolysis 19, 471-475 (2008).
12. Warkentin, T. E. & Kelton, J. G. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101, 502-507 (1996).
13. Greinacher, A. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb. Haemost. 94, 132-135 (2005).
14. Preachel, M. & walenga, J. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: An update. Semin. Thromb. Hemost. 34, 86-96 (2008).
15. O? Toole, R. D. Heparin: adverse reaction. Ann. Intern. Med. 79, 759 (1973).
16. Warkentin, T. E. et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127, 804-812 (1997).
17. Warkentin, T. E. Clinical picture of heparin-induced thrombocytopenia. in Heparin-Induced Thrombocytopenia, 3rd edn (eds warkentin, T. E. & Greinacher, A.) 21-66 (Marcel Dekker, New York, 2007).
18. Hartman, V., Malbrain, M., Daelemans, R., Meersman, P. & Zachée, P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HiT antibodies. Nephron Clin. Pract. 104, c143-c148 (2006).
19. Davenport, A. sudden collapse during haemodialysis due to immune-mediated heparin-induced thrombocytopenia. Nephrol. Dial. Transplant. 21, 1721-1724 (2006).
20. Amiral, J. et al. Pathogenicity of igA and/or igM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J. Haematol. 92, 954-959 (1996).
21. Kelton, J. G. et al. immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83, 3232-3239 (1994).
22. Cines, D. B., Tomaski, A. & Tannenbaum, S. immune endothelial-cell injury in heparin-associated thrombocytopenia. N. Engl. J. Med. 316, 581-589 (1987).
23. Blank, M. et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int. Immunol. 14, 121-129 (2002).
24. Warkentin, T. E. & Greinacher, A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 126, 311s-337s (2004).
25. Warkentin, T. E., Aird, W. C. & rand, J. H. Platelet-endothelial interactions: sepsis, HiT and antiphospholipid syndrome. Hematology Am. Soc. Hematol. Educ. Program 1, 497-519 (2003).
26. Lo, G. K. et al. evaluation of pretest clinical score (4 T?s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost. 4, 759-765 (2006).
27. Pouplard, C. et al. Prospective evaluation of the "4Ts" score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J. Thromb. Haemost. 5, 1373-1379 (2007).
28. Greinacher, A. et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 34, 381-385 (1994).
29. Alberio, L. Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment. Curr. Opin. Hematol. 15, 456-464 (2008).
30. Lo, G. K., sigouin, C. S. & warkentin, T. E. what is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am. J. Hematol. 82, 1037-1043 (2007).
31. Warkentin, T. E. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330-1335 (1995).
32. Prandoni, P., siragusa, S., Girolami, B., Fabris, F. & BeLZONi investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106, 3049-3054 (2005).
33. Lee, D. P. & warkentin, T. E. Frequency of heparin-induced thrombocytopenia. in Heparin-Induced Thrombocytopenia, 2nd edn (eds warkentin, T. E. & Greinacher, A.) 87-122 (Marcel Decker, New York, 2001).
34. Yamamoto, S. et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am. J. Kidney Dis. 28, 82-85 (1996).
35. Greinacher, A., Zinn wizemann, S. & Birk, U. W. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 348, 764 (1996).
36. Sitter, T., spannagl, M., Banas, B. & schiffl, H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 79, 245-246 (1998)
37. De sancho, M., Lema, M. G., Amiral, J. & rand, J. Frequencies of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. Thromb. Haemost. 75, 693-699 (1996).
38. Boon, D. M., van vliet, H. H., Zietse, R. & Kappers-Klunne, M. C. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb. Haemost. 76, 480 (1996).
39. O?shea, S. I., sands, J. J., Nudo, S. A. & Ortel, T. L. Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am. J. Hematol. 69, 72-73 (2002).
40. Matsuo, T. et al. Frequency of anti-heparin-PF4 complex antibodies (HiT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol. Haemost. Thromb. 35, 445-450 (2006).
41. Yu, A., Jacobson, S. H., Bygdén, A. & egberg, N. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin. Chem. Lab. Med. 40, 21-26 (2002).
42. Carrier, M. et al. increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int. 73, 213-219 (2008).
43. Luzzatto, G. et al. Platelet count, anti-heparin/ platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb. Res. 89, 115-122 (1998).
44. De la vega, L. P. et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin. Proc. 80, 995-1000 (2005).
45. Mureebe, L. et al. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 136, 848-853 (2004).
46. Palomo, I. et al. Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J. Clin. Lab. Anal. 19, 189-195 (2005).
47. Nakamoto, H. et al. role of platelet Factor 4-heparin complex antibody (HiT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial. Int. 9 (Suppl. 1), s2-s7 (2005).
48. Asmis, L. M. et al. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb. Haemost. 100, 498-504 (2008).
49. Lasocki, S. et al. Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study. Crit. Care 12, r84 (2008).
50. Warkentin, T. E. & Kelton, J. G. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101, 502-507 (1996).
51. Moberg, P. Q., Geary, V. M. & sheikh, F. M. Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters. J. Cardiothorac. Anesth. 4, 226-228 (1990).
52. Kaplan, G. G., Manns, B. & McLaughlin, K. Heparin induced thrombocytopaenia secondary to intraperitoneal heparin exposure. Nephrol. Dial. Transplant. 20, 2561-2562 (2005).
53. Fischer, K. G. Hemodialysis in heparin-induced thrombocytopenia. in Heparin-Induced Thrombocytopenia, 3rd edn (eds warkentin, T. E. & Greinacher, A.) 463-485 (New York, Marcel Dekker, 2007).
54. Nowak, G., Bucha, E., Gööck, T., Thieler, H. & Markwardt, F. Pharmacology of r-hirudin in renal impairment. Thromb. Res. 66, 707-715 (1992).
55. Keeling, D. et al. The management of heparin-induced thrombocytopenia. Br. J. Haematol. 133, 259-269 (2006).
56. Linkins, L. A. & warkentin, T. E. The approach to heparin-induced thrombocytopenia. Semin. Respir. Crit. Care Med. 29, 66-74 (2008).
57. O?shea, S. I., Ortel, T. L. & Kovalik, E. C. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin. Dial. 16, 61-67 (2003).
58. Warkentin, T. E. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (Suppl. 6), 340s-380s (2008).
59. Vanholder, R. et al. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb. Haemost. 77, 650-655 (1997).
60. Greinacher, A., eichler, P., Lubenow, N., Kwasny, H. & Luz, M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96, 846-851 (2000).
61. Badger, N. O., Butler, K. & Hallman, L. C. excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia. Pharmacotherapy 24, 1800-1803 (2004).
62. Bauersachs, R. M. et al. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb. Haemost. 81, 323-324 (1999).
63. Frank, R. D., Farber, H., stefanidis, I., Lanzmich, R. & Kierdorf, H. P. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int. 56 (Suppl. 72s), s41-s45 (1999).
64. Benz, K., Nauck, M. A., Böhler, J. & Fischer, K. G. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. Clin. J. Am. Soc. Nephrol. 2, 470-476 (2007).
65. Lubenow, N. & Greinacher, A. Heparin-induced thrombocytopenia. recommendations for optimal use of recombinant hirudin. Biodrugs 14, 109-125 (2000).
66. Nowak, G. & Bucha, E. Quantitative determination of hirudin in blood and body fluids. Semin. Thromb. Hemost. 22, 197-202 (1996).
67. Guy, S. et al. The use of ecarin chromogenic assay and prothrombin induced clotting time in the monitoring of lepirudin for treatment of heparin-induced thrombocytopenia. Br. J. Haematol. 142, 466-468 (2008).
68. Athar, U., Husain, J., Hudson, J., Lynch, J. & Gajra, A. Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia. Am. J. Hematol. 83, 245-246 (2008).
69. Di Nisio, M., Middeldorp, S. & Büller, H. R. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040 (2005).
70. Lewis, B. E., wallis, D. E., Hursting, M. J., Levine, R. L. & Leya, F. effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129, 1407-1416 (2006).
71. Swan, S. W. & Hursting, M. J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20, 318-329 (2000).
72. Link, A. et al. Argatroban for anticoagulation in continuous renal replacement therapy. Crit. Care Med. 37, 105-110 (2009).
73. Murray, P. T. et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 66, 2446-2453 (2004).
74. Hursting, M. J. & Murray, P. T. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin. Pract. 109, c80-c94 (2008).
75. Schneider, S. A., Nauck, M. S., Nauck, M. A. & Fischer, K.-G. Only plasmapheresis allows for danaparoid elimination from blood [abstract]. Kidney Blood Press. Res. 27, a360 (2004).
76. Dager, W. E., Dougherty, J. A., Nguyen, P. H., Militello, M. A. & smythe, M. A. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 27, 564-587 (2007).
77. Apsner, R., Buchmayer, H., Gruber, D. & sunder-Plassmann, G. Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am. J. Kidney Dis. 45, 557-564 (2005).
78. Kozik-Jaromin, J., Nier, V., Heemann, U., Kreymann, B. & Böhler, J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol. Dial. Transplant. 24, 2244-2251 (2009).
79. Hartman, V., Malbrain, M., Daelemans, R., Meersman, P. & Zachée, P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HiT antibodies. Nephron Clin. Pract. 104, c143-c148 (2006).
80. Davenport, A. HiT on dialysis when is it safe to rechallenge? Nephron Clin. Pract. 104, c149-c150 (2006).
81. Matsuo, T., Kusano, H., wanaka, K., ishihara, M. & Oyama, A. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin. Appl. Thromb. Haemost. 13, 182-187 (2007).
82. Pötzsch, B., Klövekorn, W. P. & Madlener, K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343, 515 (2000).
83. Greinacher, A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin. Thromb. Hemost. 30, 315-327 (2004).
84. Selleng, S., Lubenow, N., wollert, H. G., Müllejans, B. & Greinacher, A. emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia. Ann. Thorac. Surg. 71, 1041-1042 (2001).
85. Lubenow, N. et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann. Thorac. Surg. 75, 577-579 (2003).